| Abstract | We describe a patient with congenital afibrinogenemia who showed elevated prothrombin activation fragments (F1 + 2) indicating increased thrombin formation. This finding was unexpected since it has hitherto been thought that patients with congenital hypo- or afibrinogenemia have no evidence of increased utilization or accelerated consumption of coagulation factors. No other possible reasons for the elevation of F 1 + 2 were found. Upon fibrinogen substitution F1 + 2 decreased and were again increasing when fibrinogen concentration in plasma fell to very low levels. These findings raise the question of whether increased thrombin formation should be understood as a compensatory mechanism in congenital afibrinogenemia. |
| Authors | W Korte, A Feldges
(Affiliation: Institut für Klinische Chemie und Hämatologie, Kantonsspital, St. Gallen, Schweiz.)
|
| Journal | The Clinical investigator
(Clin Investig)
Vol. 72
Issue 5
Pg. 396-8
(May 1994)
ISSN: 0941-0198 GERMANY |
| PMID | 8086775
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Fibrin Fibrinogen Degradation Products
- Peptide Fragments
- fibrin fragment D
- prothrombin fragment 1.2
- Prothrombin
- Fibrinogen
|
| Topics |
- Adolescent
- Afibrinogenemia
(blood, drug therapy)
- Enzyme Activation
- Female
- Fibrin Fibrinogen Degradation Products
(analysis)
- Fibrinogen
(therapeutic use)
- Humans
- Peptide Fragments
(analysis)
- Prothrombin
(analysis, metabolism)
|
